Kidney Week 2024 Live Event: October 24th - Day #1 - 10/24/2024
UChicago Medicine's current clinic on Salt Creek Lane in Hinsdale will close Nov. 21, and open across the street in a new, larger facility Dec. 2.
Alyssa Stolarik, RN, BSN, clinical coordinator of Cardiology at Hackensack Meridian Health Mountainside Medical Center, received the Second Best Research Poster Award at the American College of Cardiology (ACC) Quality Summit held in San Antonio, Texas. Her work, titled 鈥淚mproving Compliance with Post-PCI Creatinine,鈥� highlights significant advancements in the management of post-procedural care and patient outcomes. The research addresses the critical issue of acute kidney injury (AKI) post-percutaneous coronary intervention (PCI), demonstrating a marked reduction in risk-standardized AKI rates, which significantly surpasses national benchmarks.
Jiang He, M.D., Ph.D., Professor and Chair Designate of Epidemiology in the Peter O鈥橠onnell Jr. School of Public Health at UT Southwestern Medical Center, is a 2024 recipient of the American Heart Association鈥檚 (AHA) highest commendation, the Distinguished Scientist award. The honor recognizes Dr. He鈥檚 prolific research on reducing the risks of cardiometabolic diseases, including heart disease, stroke, obesity, Type 2 diabetes, hypertension, dyslipidemia, and chronic kidney disease.
Researchers from both Johns Hopkins Medicine and Yale University collaborated on the development and application of a diagnostic model to detect acute interstitial nephritis (AIN) in patients, which could have a lasting impact on getting patients diagnosed earlier
The article, Safety of Kidney Transplantation from Donors with HIV, details findings supporting HIV-to-HIV kidney transplants as safe and just as effective as those using organs from donors without HIV.
In patients with chronic kidney disease, the loss of podocytes鈥攑art of the kidney鈥檚 glomerular filtration barrier鈥攃auses irreversible disease progression. So far, physicians and researchers have found no way to effectively prevent podocyte damage, loss, and deterioration leading to end-stage kidney disease.
Most small kidney stones can pass on their own. However, kidney stones that are too large to pass on their own or cause bleeding, kidney damage or ongoing urinary tract infections may require surgical treatment. Dr. Aaron Potretzke, a Mayo Clinic urologist in Rochester, Minnesota, explains some of the different surgical options for removing kidney stones.
A maioria dos c谩lculos renais podem ser expelidos por conta pr贸pria. "No entanto, os c谩lculos renais que s茫o grandes demais para serem expelidos sozinhos ou que causam sangramento, danos nos rins ou infec莽玫es urin谩rias recorrentes podem exigir tratamento cir煤rgico." O Dr. Aaron Potretzke, urologista da Mayo Clinic em Rochester, Minnesota, explica algumas das op莽玫es cir煤rgicas para remover os c谩lculos renais.
La mayor铆a de los c谩lculos renales pueden ser expulsados por su cuenta. "Sin embargo, los c谩lculos renales que son demasiado grandes para ser expulsados por s铆 solos o que causan sangrado, da帽o renal o infecciones urinarias recurrentes pueden requerir tratamiento quir煤rgico." El Dr. Aaron Potretzke, ur贸logo en Mayo Clinic en Rochester, Minnesota, explica algunas de las opciones quir煤rgicas para extirpar los c谩lculos renales.
賷購賲賰賳 賱賲毓馗賲 丨氐賵丕鬲 丕賱賰賱賶 丕賱氐睾賷乇丞 兀賳 鬲賲購乇 亘卮賰賱 胤亘賷毓賷. 賵賲毓 匕賱賰貙 賮廿賳 丨氐賵丕鬲 丕賱賰賱賶 丕賱賰亘賷乇丞 噩丿賸丕 丕賱鬲賷 賱丕 賷賲賰賳賴丕 丕賱禺乇賵噩 賲賳 鬲賱賯丕亍 賳賮爻賴丕 兀賵 鬲爻亘亘 丕賱賳夭賷賮 兀賵 鬲賱賮 丕賱賰賱賶 兀賵 丕賱鬲賴丕亘丕鬲 丕賱噩賴丕夭 丕賱亘賵賱賷 丕賱賲爻鬲賲乇丞 賯丿 鬲鬲胤賱亘 鬲丿禺賱丕賸 噩乇丕丨賷賸丕. 賷卮乇丨 丕賱丿賰鬲賵乇 丌乇賵賳 亘賵鬲乇鬲夭賰賷貙 兀禺氐丕卅賷 丕賱賲爻丕賱賰 丕賱亘賵賱賷丞 賮賷 賲丕賷賵 賰賱賷賳賷賰 亘乇賵鬲卮爻鬲乇貙 賲賷賳賷爻賵鬲丕貙 亘毓囟 丕賱禺賷丕乇丕鬲 丕賱噩乇丕丨賷丞 賱廿夭丕賱丞 丨氐賵丕鬲 丕賱賰賱賶.
Findings from Rutgers Health and other researchers may lead to more precise treatment.
Kidney Week 2024: Live Event
The National Institutes of Health awarded a four-year, $2.6 million grant to researchers at Case Western Reserve University to study how high blood-pressure drugs affect patients with chronic kidney disease (CKD).
Dr. Roy-Chaudhury will head up an organization鈥攚ith nearly 21,000 health professionals representing 140 countries鈥攄edicated to leading the fight against kidney diseases.
IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition鈥檚 pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23鈥� 27.
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients鈥� kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23鈥� 27.
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)鈥攁 procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23鈥�27.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
